Evidence map›Paper›PMID 38310435›Full record

ArticleArchives of Iranian medicine2023

Elevated Plasma Levels of MT4-MMP and MT6-MMP; A New Observation in Patients with Thyroid Nodules.

Khadijeh Shirazkeytabar, S Adeleh Razavi, Raziyeh Abooshahab, Pouya Salehipour, Mahdi Akbarzadeh, Ahmadreza Soroush, Mehdi Hedayati, Shirzad Nasiri

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of Iranian medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Khadijeh ShirazkeytabarDepartment of Surgery, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-9125-4932
S Adeleh RazaviCellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Raziyeh AbooshahabCellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pouya SalehipourDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi AkbarzadehCellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ahmadreza SoroushDepartment of Surgery, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mehdi HedayatiCellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-5816-775X
Shirzad NasiriDepartment of Surgery, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-7267-9890
Shariati Hospital · IRCurtin University · AUTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on the critical role of MT4-MMP and MT6-MMP in carcinogenesis, we focused on MT4-MMP and MT6-MMP circulating levels in patients with thyroid nodules.

methodsPlasma samples were collected from three groups, including papillary thyroid cancer (PTC; n=30), multinodular goiter (MNG; n=30), and healthy subjects (n=22). Enzyme-linked immunosorbent assay (ELISA) was used to obtain the concentration of MT4-MMP and MT6-MMP in the three groups.

resultsAnalysis of data demonstrated increased levels of MT4-MMP (PTC: 4.90±1.35, MNG: 4.89±1.37, and healthy: 3.13±1.42) and MT6-MMP (PTC: 8.29±2.50, MNG: 7.34±2.09, and healthy:5.01±2.13) in thyroid nodules by comparison with healthy subjects (

conclusionOur work has led us to imply that the higher levels of MT4-MMP and MT6-MMP are closely linked with both PTC and MNG tumorigenesis. They may probably promote the development of thyroid lesions; however, more research is needed to further clarify the current findings.

Indexed as

Matrix Metalloproteinase 17Matrix Metalloproteinases, Membrane-AssociatedThyroid NeoplasmsThyroid NoduleCarcinogenesisGPI-Linked ProteinsHumansGPI-Linked ProteinsMatrix Metalloproteinase 17matrix metalloproteinase 25Matrix Metalloproteinases, Membrane-AssociatedMMP17 protein, humanGlycosyl-phosphatidyl inositolMatrix metalloproteinasesMT4-MMPMT6-MMPThyroid nodules

Identifiers

PMID38310435
PMCPMC10685831
OpenAlexW4387425368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.